{"id":"NCT02013544","sponsor":"EndoCeutics Inc.","briefTitle":"Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2015-01","completion":"2015-02","firstPosted":"2013-12-17","resultsPosted":"2017-06-01","lastUpdate":"2017-06-01"},"enrollment":558,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Vaginal Atrophy"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Prasterone (DHEA)","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Prasterone","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on symptoms of vulvovaginal atrophy due to menopause and to collect further data on subjects exposed to intravaginal DHEA in order to meet the ICH E1 guideline requirements.","primaryOutcome":{"measure":"Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":1.04,"sd":0.11},{"arm":"0.50% Prasterone (DHEA)","deltaMin":1.02,"sd":0.08}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":38,"countries":["United States","Canada"]},"refs":{"pmids":["26291918","26597311","26517756","26731686","26972555","26634942"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":180},"commonTop":["Application site discharge"]}}